GlobeNewsWire
03 Dec 2025, 21:05 UTC · 46w ago
Impact · against what's priced in
Inotiv shows a strong trajectory toward profitability with a 64.2% reduction in full-year operating losses and a significant 61% jump in DSA net awards. The combination of top-line growth and aggressive cost management creates a positive catalyst for the stock.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
Inotiv's full-year fiscal 2025 operating loss decreased by 64.2% to $30.9 million compared to $86.4 million in the prior year.
More positive than 94% of claims this week
Drug Safety Assessment (DSA) net awards increased by approximately 61% over the prior year quarter.
Continue reading
5 related stories
The company demonstrated strong operational improvement with FY2025 operating losses falling to $30.9 million from $86.4 million and a 61% increase in DSA net awards, which serves as a leading indicator for future revenue.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 88% of claims this week
Fourth quarter fiscal 2025 revenue increased 5.9% year-over-year to $138.1 million.
More positive than 68% of claims this week
Fourth quarter operating loss decreased 48.5% to $6.8 million from $13.2 million in the same period last year.
More positive than 68% of claims this week
Which stocks this story touches
More positive than 78% of ticker scores this week
The company reported year-over-year revenue growth and a significant decrease in operating losses for both the fourth quarter and the full fiscal year.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
3h ago
−91.5%
Price is moving against the score
$0.0799 vs $0.9403 close before publication (Dec 3) · not market-adjusted
NOTV chart →
